The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog.

The pharmacokinetics of oclacitinib maleate was evaluated in four separate studies. The absolute bioavailability study used a crossover design with 10 dogs. The effect of food on bioavailability was investigated in a crossover study with 18 dogs. The breed effect on pharmacokinetics was assessed in a crossover study in beagles and mongrels dogs. Dose proportionality and multiple dose pharmacokinetics were evaluated in a parallel design study with eight dogs per group. In all four studies, serial blood samples for plasma were collected. Oclacitinib maleate was rapidly and well absorbed following oral administration, with a time to peak plasma concentration of <1 h and an absolute bioavailability of 89%. The prandial state of dogs did not significantly affect the rate or extent of absorption of oclacitinib maleate when dosed orally, as demonstrated by the lack of significant differences in pharmacokinetic parameters between the oral fasted and oral fed treatment groups. The pharmacokinetics of oclacitinib in laboratory populations of beagles and mixed breed dogs also appeared similar. Following oral administration, the exposure of oclacitinib maleate increased dose proportionally from 0.6 to 3.0 mg/kg. Additionally, across the pharmacokinetic studies, there were no apparent differences in oclacitinib pharmacokinetics attributable to sex.

[1]  A. Gonzales,et al.  Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy , 2014, Journal of veterinary pharmacology and therapeutics.

[2]  J. Tena,et al.  A blinded, randomized, placebo‐controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client‐owned dogs with atopic dermatitis , 2013, Veterinary dermatology.

[3]  J. Boucher,et al.  Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis , 2013, Veterinary dermatology.

[4]  A. Gonzales,et al.  Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis. , 2012, Journal of the American Veterinary Medical Association.

[5]  R. Coatney,et al.  Gastric pH and gastric residence time in fasted and fed conscious beagle dogs using the Bravo pH system. , 2012, Journal of pharmaceutical sciences.

[6]  M. Papich,et al.  Drug solubility classification in the dog. , 2012, Journal of veterinary pharmacology and therapeutics.

[7]  H. Kantarjian,et al.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond , 2011, Nature Reviews Drug Discovery.

[8]  V. Soumelis,et al.  A Modular View of Cytokine Networks in Atopic Dermatitis , 2011, Clinical reviews in allergy & immunology.

[9]  Fasheng Li,et al.  Fed and fasted gastric pH and gastric residence time in conscious beagle dogs. , 2009, Journal of pharmaceutical sciences.

[10]  J. O’Shea,et al.  Janus kinases in immune cell signaling , 2009, Immunological reviews.

[11]  V. Rutten,et al.  Immune dysregulation in atopic dermatitis. , 2002, Veterinary immunology and immunopathology.

[12]  K. Gough,et al.  Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party , 1995 .

[13]  Karen J. Klamerus,et al.  Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O‐Desmethyl Metabolite , 1992, Journal of clinical pharmacology.

[14]  H. Kantarjian,et al.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond , 2011, Nature Reviews Drug Discovery.

[15]  C. Brindley,et al.  Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion , 2009, Pharmaceutical statistics.

[16]  F. Vandenhende,et al.  Confidence Interval Criteria for Assessment of Dose Proportionality , 2004, Pharmaceutical Research.

[17]  P. Toutain,et al.  Plasma clearance. , 2004, Journal of veterinary pharmacology and therapeutics.